UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 87

Sortiert nach

Efavirenz 400 mg daily remains non‐inferior to 600 mg: 96 week data from the double‐blind, placebo‐controlled ENCORE1 study

Journal of the International AIDS Society, 2014-11, Vol.17 (4 Suppl 3), p.19523-n/a

Carey, Dianne

2014

Volltextzugriff (PDF)

Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection

AIDS (London), 2007-11, Vol.21 (18), p.2445-2453

2007

Volltextzugriff (PDF)

A prospective multicentre study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals

British journal of clinical pharmacology, 2004-04, Vol.57 (4), p.513-521

2004

Volltextzugriff (PDF)

Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study

Therapeutic drug monitoring, 2017-12, Vol.39 (6), p.654

2017

Volltextzugriff (PDF)

A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy

Journal of acquired immune deficiency syndromes (1999), 2007-12, Vol.46 (5), p.581

2007

Volltextzugriff (PDF)

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

Clinical pharmacokinetics, 2016-07, Vol.55 (7), p.861-873

2016

Volltextzugriff (PDF)

Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial

The Lancet (British edition), 2014-04, Vol.383 (9927), p.1474-1482

Anon

2014

Volltextzugriff (PDF)

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study

The Lancet infectious diseases, 2015-07, Vol.15 (7), p.793-802

2015

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study

Clinical pharmacology and therapeutics, 2015-10, Vol.98 (4), p.406-416

2015

Volltextzugriff (PDF)

Prospective evidence that HIV lipoatrophy and visceral adiposity are partially independent processes

Open access journal of clinical trials, 2011-01, Vol.3 (default), p.1-7

2011

Volltextzugriff (PDF)

Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials

Journal of antimicrobial chemotherapy, 2010-09, Vol.65 (9), p.1878-1888

2010

Volltextzugriff (PDF)

Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy

AIDS (London), 2018-01, Vol.32 (3), p.357-361

2018

Volltextzugriff (PDF)

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2004-02, Vol.363 (9407), p.429-438

2004

Volltextzugriff (PDF)

Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial

Clinical infectious diseases, 2015-04, Vol.60 (7), p.1026-1032

2015

Volltextzugriff (PDF)

A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults

Journal of acquired immune deficiency syndromes (1999), 2012-06, Vol.60 (2), p.143

2012

Volltextzugriff (PDF)

Simultaneous determination of indinavir, ritonavir and lopinavir (ABT 378) in human plasma by high-performance liquid chromatography

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2002-08, Vol.775 (2), p.225-230

2002

Volltextzugriff (PDF)

Effect of Rosiglitazone on Peroxisome Proliferator-Activated Receptor γ Gene Expression in Human Adipose Tissue Is Limited by Antiretroviral Drug-Induced Mitochondrial Dysfunction

The Journal of infectious diseases, 2008-12, Vol.198 (12), p.1794-1803

2008

Volltextzugriff (PDF)

Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial

AIDS (London), 2009, Vol.23 (16), p.2228-2229

2009

Volltextzugriff (PDF)

Restorative interventions for HIV facial lipoatrophy

AIDS reviews, 2008-04, Vol.10 (2), p.116-124

2008

Volltextzugriff (PDF)

Health-related quality of life outcomes in HIV-infected patients starting different combination regimens in a randomized multinational trial: the INITIO-QoL substudy

AIDS research and human retroviruses, 2007-10, Vol.23 (10), p.1215

2007

Volltextzugriff (PDF)

Once-daily therapies

Journal of HIV therapy, 2003-02, Vol.8 (1), p.7

Carey, Dianne

2003

Volltextzugriff (PDF)

Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial

AIDS (London), 2005-08, Vol.19 (12), p.1325-1327

2005

Volltextzugriff (PDF)

Poly‐l‐lactic acid for HIV‐1 facial lipoatrophy: 48‐week follow‐up

HIV medicine, 2009-03, Vol.10 (3), p.163-172

2009

Volltextzugriff (PDF)

Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy

Antiviral therapy, 2005, Vol.10 (1), p.135-143

2005

Volltextzugriff (PDF)

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Commentary

The Lancet (British edition), 2004, Vol.363 (9407), p.412-414

2004

Volltextzugriff (PDF)

1 – 25 von 87

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(86)
Dissertationen
(1)

Sprache

Englisch
(87)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Humans
(72)
Science & Technology
(71)
Life Sciences & Biomedicine
(69)
Female
(55)
Adult
(39)
Male
(36)
Biological And Medical Sciences
(32)
Medical Sciences
(32)
Middle Aged
(32)
Hiv
(24)
Infectious Diseases
(24)
Adolescent
(23)
Human Immunodeficiency Virus
(22)
Human Viral Diseases
(15)
Viral Diseases
(15)
Nursing
(14)
Aged
(13)
Hiv Infections - Drug Therapy
(13)
Viral Diseases Of The Lymphoid Tissue And The Blood. Aids
(13)
General & Internal Medicine
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efavirenz 400 mg daily remains non‐inferior to 600 mg: 96 week data from the double‐blind, placebo‐controlled ENCORE1 study

Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection

A prospective multicentre study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals

Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study

A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study

Prospective evidence that HIV lipoatrophy and visceral adiposity are partially independent processes

Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials

Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial

Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial

A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults

Simultaneous determination of indinavir, ritonavir and lopinavir (ABT 378) in human plasma by high-performance liquid chromatography

Effect of Rosiglitazone on Peroxisome Proliferator-Activated Receptor γ Gene Expression in Human Adipose Tissue Is Limited by Antiretroviral Drug-Induced Mitochondrial Dysfunction

Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial

Restorative interventions for HIV facial lipoatrophy

Health-related quality of life outcomes in HIV-infected patients starting different combination regimens in a randomized multinational trial: the INITIO-QoL substudy

Once-daily therapies

Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial

Poly‐l‐lactic acid for HIV‐1 facial lipoatrophy: 48‐week follow‐up

Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Commentary

Suchergebnisse filtern